versy persists regarding its true incidence. Generalized guidelines for the prevention and management of VAP have recently been forwarded by the Canadian Critical Care Society 4 as well as the American Thoracic Society and Infectious Disease Society of America. 5 However, the strategy used to take general guidelines and make them operational for a homogenous patient population such as trauma has not been done. In the injured population specific guidelines are especially needed for the diagnosis of VAP where pulmonary contusion may confound chest radiograph interpretation and fever, tachycardia and leukocytosis may be secondary to the systemic inflammatory response (SIRS) induced by the injury. Strict definitions for the diagnosis of VAP along with appropriate antibiotic treatment guidelines may result in fewer patients without VAP being treated and reduce antimicrobial resistance.
As part of the Inflammation and the Host Response to Injury Large-Scale Collaborative Research Program, the participating investigators took existing evidence-based data and guidelines for prevention, diagnosis and treatment of VAP and developed a standard operating procedure (SOP) to manage these patients. These procedures do not address prevention strategies related to ventilator maintenance (circuit changes, humidifiers, suction devices, etc.), but are focused on prevention strategies targeting direct clinical patient care. The primary purpose of this SOP was to standardize the manner in which trauma patients are managed in relation to prevention, diagnosis and treatment of VAP across the centers enrolling patients into the Program's clinical trials. No attempt was made to re-classify and grade all available evidence, rather the goal was to develop a uniform approach to injured patients from evidence based guidelines and data already in print.
Protocol Goals
• Reduce the incidence of VAP in ventilated trauma patients using standardized prevention strategies.
• Define the necessary clinical criteria for the diagnosis of VAP in patients with suspected VAP.
• Provide clinical guidelines for the treatment of VAP that ensures antimicrobial therapy is initiated and discontinued appropriately.
Protocol Rationale

Prevention of Ventilator-Associated Pneumonia (VAP)
Most episodes of VAP occur as a result of aspiration of contaminated oropharyngeal and to a lesser extent gastric secretions around the endotracheal tube. While hematogenous spread from a distant site can occur, it is considered rare in comparison to direct micro-or macro-aspiration. Thus, prevention of VAP can be most effectively accomplished with a number of strategies directed at either decreasing the microbiologic load of the aspirate, and/or minimizing the volume of aspirate.
The greatest risk factor for the development of VAP is the duration of mechanical ventilation. The longer patients are intubated with an endotracheal tube, the greater the risk for the development of VAP. Thus, an important and sometimes overlooked prevention strategy is implementing a ventilator management strategy that ensures liberation from the ventilator at the earliest time. To this aim, the Inflammation and the Host Response to Injury Large-Scale Collaborative Research Program has previously published their Ventilator Management Guideline in this Journal. 6 Institution of an ICU oral hygiene program has been shown to be effective in decreasing the incidence of VAP. There is Level II evidence showing that use of the antiseptic agent chlorhexidine gluconate, as part of an oral hygiene program of frequent tooth-brushing, and deep suctioning of oral and pharyngeal/subglottic secretions, is associated with a reduction in the incidence of VAP in trauma patients. 7 Techniques that minimize the volume of aspirate have also been shown to be effective in decreasing VAP rates. In patients whose injuries do not specify the need for supine positioning, elevation of the head of the bed greater than 30°f rom horizontal has been shown to be an effective VAP prevention measure. In those that must remain supine, reverse Trendelenberg positioning can be effective. Level I evidence from a randomized controlled trial, has shown the relative risk reduction of this relatively simple intervention was almost 80%, 8 with the principal VAP risk factors in this study being supine positioning and enteral feeding. As a corollary, prevention of gastric distention and vomiting or gross reflux with naso-or oro-gastric tube should be routine. These tubes should be removed at the earliest clinically appropriate time to maintain the integrity of the lower esophageal sphincter. Additionally, sucralfate or H2-blockers should be used for stress gastritis prophylaxis as they are equally effective in preventing stress-induced bleeding. Antacids should be avoided since the volume and dwell time required to effectively mitigate bleeding poses an increased risk for aspiration. Early surgical feeding access either at the time of initial abdominal surgery or with percutaneous techniques in those with prolonged need for intubation (e.g. traumatic brain injury) should also be considered.
Minimizing transfer of contaminating organisms from the health-care worker to patient decreases a number of nosocomial infections including VAP. Transmission of microorganisms from health-care workers hands to patients and devices, including ventilator circuits and endotracheal tubes, is well documented. There is Level I evidence to show handwashing, including frequent use of alcohol-based antiseptic preparations as well as frequent health-care worker glove change, is associated with a reduction in nosocomial infections. 9 Recent studies from ICUs that have instituted a number of the above described VAP prevention strategies together as a "VAP prevention bundle" have been highly successful with reductions in VAP rates that approach 50%. 10 Further, out-
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Standard Operating Procedure for the Diagnosis of VAP
The diagnosis of VAP has been made on the basis of a constellation of signs and symptoms, including fever, leukocytosis, abnormal findings on chest x-ray and production of purulent respiratory secretions, which when cultured, reveal pathogenic organisms on Gram's stain and microbiologic culture results. Unfortunately, there is no consensus on which combination of findings yields an accurate diagnosis of VAP. This poses difficulty in the injured patient where pulmonary contusions and aggressive resuscitation along with a concomitant reperfusion injury can result in an abnormal chest radiograph and the systemic inflammatory response syndrome (SIRS), common in severely injured patients, can mimic infection.
The clinical pulmonary infection score (CPIS, see Table  1 ) has been developed to estimate the likelihood that a patient has nosocomial pneumonia. In a group of hospitalized medical patients, those with a score of Յ 6 had a low probability of having pneumonia when compared with those with a score of Ͼ 6.
11 Further, when the CPIS was used to guide antimicrobial therapy, there was less antimicrobial use and a reduction in the risk of infections due to resistant organisms. Unfortunately, using the CPIS Ͼ 6 threshold by itself for a diagnosis of VAP is neither sensitive nor specific. In a retrospective review of prospectively collected data, CPIS was compared with quantitative broncho-alveolar lavage (BAL) cultures to evaluate the operating characteristics of CPIS Ͼ 6 in the diagnosis of VAP. Of 113 patients who did not have VAP (quantitatively negative BAL cultures), 53 had a CPIS Յ 6, and 60 had a CPIS Ͼ 6. Of the 88 patients that had VAP diagnosed by quantitatively positive BAL cultures, 10 had CPIS Յ 6, and 78 had a CPIS Ͼ 6. This resulted in a sensitivity, specificity, positive predictive value and negative predictive value of 89%, 47%, 57% and 84% respectively. 12 Thus, based on Level II evidence, this SOP does NOT use CPIS independently to diagnose VAP. However, CPIS is used as an initial screening tool to identify patients who may be at a higher likelihood of having a diagnosis of VAP, acknowledging that the variable presentation of VAP seen in trauma patients may lead to a variety of clinical parameters that heighten suspicion for a diagnosis of VAP. Thus, the purpose of including CPIS in the SOP was to standardize and quantify the factors that increase clinical suspicion for VAP across the participating centers and assure that patients would have quantitative cultures obtained for similar clinical criteria.
In patients who have elevated CPIS scores, VAP diagnosis is only confirmed after results of respiratory cultures are known. Routine sputum specimens collected from an endotracheal tube are notoriously non-specific in the diagnosis of VAP as the endotracheal tube and trachea quickly become colonized shortly after intubation. Most recent data that evaluate the criteria for treatment with antibiotics in a presumed diagnosis of VAP have utilized semi-quantitative or quantitative protected sampling of the lower respiratory tract. Semiquantitative and quantitative cultures, while not 100% sensitive and specific, can help distinguish between colonization and infection. 13 Croce and colleagues were the first to show the importance of using quantitative cultures in injured patients to distinguish VAP from those with non-infectious systemic inflammatory response syndrome. 14 There are a number of techniques that can be utilized to obtain respiratory samples for quantitative culture evaluation. These include bronco-alveolar lavage (BAL) obtained bronchoscopically, BAL obtained non-bronchoscopically using protected or telescoping catheters, and protected specimen brush (PSB). However, there is no gold standard, even when compared with autopsy, 15 but a therapeutic strategy with BAL as the cornerstone of diagnosis, has been shown to reduce mortality. 16 In a recent randomized, controlled multicenter study, management strategies based on an invasive quantitative diagnosis (BAL or PSB) were associated with improved 14-day survival, earlier improvement from organ dysfunction and decreased antibiotic complications compared with a strategy based on clinical criteria and routine endotracheal sputum culture without protected lower respiratory tract sampling. 16 Based on Level I evidence, we present standard operating procedures for the diagnostic approach to VAP. 17 The most common organisms isolated from respiratory cultures of patients suspected of VAP are S. aureus and P.aeruginosa. The most recent CDC surveillance data suggests that methicillin-resistant S. aureus accounts for nearly 60% of all S. aureus isolates in the ICU. Likewise, resistant P. aeruginosa is a growing ICU problem with carbapenem, quinolone and 3 rd -generation cephalosporin resistance measured at 21%, 30% and 32% respectively.
1 Empiric antimicrobial coverage should account for the resistance patterns of common pathogenic isolates in any particular unit. Once microbiologic results including sensitivities are known, "de-escalation" of antimicrobial coverage to fit the culture results is indicated, using the most narrowly focused antibiotics appropriate. The concept of stopping antibiotics if quantitative cultures are less than threshold values is supported in the literature. 16 It has also been shown that unnecessary use of antibiotics for VAP increases the likelihood of superinfection with multi-resistant organisms. 2 The duration of antibiotic treatment for a confirmed case of VAP has received considerable attention in the literature. Recent data suggests that antibiotics can be stopped once clinical signs of infection have resolved. This may also decrease the incidence of secondary pneumonias with multiresistant organisms. 18, 19 A recent study showed that an antibiotic discontinuation policy based on a pre-defined clinical response to antimicrobial therapy was associated with a shorter duration of antibiotic use and no difference in the occurrence of secondary VAP episodes when compared with conventional antibiotic management. Generally, antibiotic duration was on average 2 days less in the group that followed the antibiotic discontinuation policy and totaled approximately six days. 19 There is some biological rationale for shorter courses of antibiotics for VAP. One study followed daily cultures and clinical signs for 2 weeks after diagnosis of VAP. These authors showed that most clinical signs had resolved by day 6 of therapy and that in the case of H. influenzae and S. pneumoniae all organisms were eradicated. Enterobacteriaceae, S. aureus, and P. aeruginosa persisted despite in vitro sensitivity and suggests that the airway will remain colonized with these organisms no matter how long the course of antibiotics. 20 In a multi-center randomized trial there were no differences in mortality or recurrent infection between patients with quantitative culture positive VAP who were treated for 8 days of antibiotics versus those treated for 15 days. Those treated 15 days had greater antibiotic use and greater emergence of multi-resistant organisms, while the subset of patients who grew non-lactose fermenting organisms such as P. aeruginosa and A. Baumanii had more recurrent infections when treated for 8 days. 21 Based on Level I and II evidence presented, standard operating procedures for the treatment of VAP is presented. 22 Standardized techniques should be utilized for obtaining and processing quantitative samples. Controversy exists regarding the quantitative threshold that is required to make a diagnosis of VAP. In the trauma population, independent data from Croce 23 and from Miller 24 support a diagnostic threshold Ն 100,000 colony forming units(CFU)/mL of lavage fluid. The CDC criteria support a diagnostic threshold Ն 10,000 CFU/mL. Utilizing the higher threshold will result in more false negative diagnosis; a rate that both Croce and Miller suggest is approximately 15% of cases. Alternatively the lower threshold potentially results in over-treating patients who do not have VAP. In the absence of definitive evidence to support any threshold, the members of this Large Scale Collaborative Program chose to use a threshold Ն 10,000 CFU/mL to minimize the risk of not treating a patient with VAP. Suspicion of VAP should prompt rapid procurement (i.e. less than 4 -6 hours) of lower respiratory tract invasive specimens for quantitative culture, before institution of antimicrobial therapy, but should not delay
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Volume 60 • Number 5therapy in critically ill patients. D. Broad spectrum empiric antibiotics should be started as soon as the sample for quantitative analysis has been obtained. Antibiotic choice should be based on unit-specific antibiograms. A regimen should be chosen that will cover the pathogenic organisms most likely to be retrieved from pulmonary cultures. E. Antimicrobial therapy should be discontinued if quantitative cultures do not meet or exceed the threshold level of growth. F. If the growth of quantitative cultures exceeds the threshold for the technique employed then antibiotics should be continued and adjusted or "de-escalated" based on culture and sensitivity results. Antibiotics should be stopped once resolution of clinical signs for greater than 24 hours has occurred. In the absence of symptom resolution, antibiotics should be stopped after 7-8 days of therapy. 5 Patients should be reassessed for signs of infection recurrence, particularly if the initial culture returned non-lactose fermenting gram-negative rods.
Protocol Details
Strategies to Prevent Ventilator-Associated Pneumonia 1. Standardized ventilator weaning protocol. This protocol should include daily evaluation for readiness to undergo a spontaneous breathing trial. Spontaneous breathing trials should be performed when indicated. Patients should be liberated from the ventilator shortly after passing their spontaneous breathing trial. The protocol used by this Large Scale Collaborative Project has been previously described. 6 2. Oral hygiene program for all intubated patients. This program should include hygiene at least once every eight-hour shift. This program should include tooth brushing, tongue and gum brushing, and irrigation and suctioning of the oropharynx. 
Diagnosis of Ventilator-Associated Pneumonia
An algorithm for the diagnosis and treatment of VAP is presented in Figure 1 ii. Bronchoscopic protected specimen brush: Ͼ 10 3 colony forming units/mL Those patients with quantitative cultures that do not meet CDC threshold will not be given a diagnosis of VAP. Treatment of VAP 1 . The treatment of VAP should depend on the unit-specific local antibiogram. Empiric treatment directed against likely pathogens should be instituted as soon as possible after cultures are obtained. 2. Empiric antibiotic treatment should be directed at the common sensitivities of pathogenic organisms typically found in the respiratory cultures from the ICU. Inclusion of grampositive coverage with activity against MRSA and broadspectrum combination therapy for P. aeruginosa should be considered. 3. Once culture results and sensitivities are known therapy should be tailored to the narrowest possible antibiotic selection possible (de-escalation). If, after 48 -72 hours, quantitative cultures do not meet CDC threshold for VAP, then antibiotics should be stopped. 4. The duration of antibiotic treatment should be based on the patient's clinical response. 5 Antibiotics should be continued until the patient has had an appropriate clinical response, is afebrile with a normal leukocyte count, and has diminished sputum production and improving respiratory status for at least 24 hours. Predetermined lengths of treatment for 10, 14 or 21 days should not be followed. In most cases, an appropriate clinical response will be noted and antibiotics can be stopped in 6 -8 days. Consideration for longer antibiotic courses may be entertained if the patient remains either febrile or has a continued leukocytosis, particularly when nonlactose fermenting organisms are cultured.
Summary
Ventilator-associated pneumonia remains a common, difficult clinical problem in the trauma ICU. This paper describes the current procedures used by the clinical centers participating in The Inflammation and Host Response to Injury Large Scale Collaborative Program. It is evidence based where good evidence exists and relies on expert opinion where there is a void. The goal of this SOP was to standardize the management of injured patients across multiple study sites. The value of SOP adherence is to minimize variability in clinical care and study outcomes on large numbers of similar patients. It should be appreciated that this SOP is dynamic and will undergo change as new data are identified.
